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Introduction: Midazolam and propofol used alone for long-term sedation are associated with adverse effects.
Sequential use may reduce the adverse effects, and lead to faster recovery, earlier extubation and lower costs. This
study evaluates the effects, safety, and cost of midazolam, propofol, and their sequential use for long-term sedation
in critically ill mechanically ventilated patients.
Methods: A total of 135 patients who required mechanical ventilation for >3 days were randomly assigned to
receive midazolam (group M), propofol (group P), or sequential use of both (group M-P). In group M-P, midazolam
was switched to propofol until the patients passed the spontaneous breathing trial (SBT) safety screen. The primary
endpoints included recovery time, extubation time and mechanical ventilation time. The secondary endpoints were
pharmaceutical cost, total cost of ICU stay, and recollection to mechanical ventilation-related events.
Results: The incidence of agitation following cessation of sedation in group M-P was lower than group M (19.4%
versus 48.7%, P = 0.01). The mean percentage of adequate sedation and duration of sedation were similar in the three
groups. The recovery time, extubation time and mechanical ventilation time of group M were 58.0 (interquartile range
(IQR), 39.0) hours, 45.0 (IQR, 24.5) hours, and 192.0 (IQR, 124.0) hours, respectively; these were significantly longer than the
other groups, while they were similar between the other two groups. In the treatment-received analysis, ICU duration was
longer in group M than group M-P (P = 0.016). Using an intention-to-treat analysis and a treatment-received analysis,
respectively, the pharmaceutical cost of group M-P was lower than group P (P <0.01) and its ICU cost was lower than
group M (P <0.01; P = 0.015). The proportion of group M-P with unbearable memory of the uncomfortable events was
lower than in group M (11.7% versus 25.0%, P <0.01), while the proportion with no memory was similar (P >0.05). The
incidence of hypotension in group M-P was lower than group (P = 0.01).
Conclusion: Sequential use of midazolam and propofol was a safe and effective sedation protocol, with higher clinical
effectiveness and better cost-benefit ratio than midazolam or propofol used alone, for long-term sedation of critically ill
mechanically ventilated patients.
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Critically ill, mechanically ventilated patients receive sed-
ation to eliminate or relieve their anxiety and discomfort;
to facilitate specific procedures such as tracheal suctioning
and frequent venipuncture; to reduce oxygen consump-
tion; and to decrease complications such as unplanned
extubation. An ideal sedative should have a rapid onset, a
short duration of action, a lack of accumulation, ease of
titration and administration, and no cardiovascular and
respiratory depression [1,2]. Until now, clinicians have
been struggling to identify the ideal drug candidates to
treat critically ill patients.
Recent surveys showed that midazolam and propofol
remain the dominant medications used for ICU sedation
[3-5]. The two drugs are equally safe and effective for
short-term sedation [6,7]. However, each drug is associated
with adverse effects when used for long-term sedation.
Treatment with midazolam may cause acute withdrawal
syndrome and delayed recovery from drug accumulation,
especially in patients with chronic renal failure [6-13].
Propofol treatment causes dose-dependent effects and
faster recovery with no accumulation [6,7,12,13]. However,
propofol may cause hypertriglyceridemia and cardio-
vascular depression, and is associated with the risk of
propofol infusion syndrome and high pharmaceutical
cost [7,8,11,13-16]. In view of the limitations associated
with these drugs when used alone, our study evaluated
whether the sequential use of midazolam and propofol
in the long-term sedation of critically ill, mechanically
ventilated patients, reduced the adverse effects.Materials and methods
Patients
We conducted a single-center, randomized, open-label
trial in West China Hospital of Sichuan University,
Sichuan, China during March 2010 to September 2011.
The study was approved by the ethics committee of West
China Hospital of Sichuan University in accordance with
the Helsinki Declaration. Written informed consent was
obtained from the patients’ authorized surrogates. Crit-
ically ill patients (n = 135) undergoing mechanical ven-
tilation were enrolled in this study within 1 hour of
admission to the ICU. Patients transferred to the 132-bed
multidisciplinary closed ICU from the medical, surgical,
and other departments (intubated) were considered for
the study.
Patients were selected based on the following inclusion
criteria: intubated patients (>18 years old) who were
expected to receive long-term (≥72 hours) mechanical
ventilation on admission to the ICU. The exclusion criteria
of the study were as follows: known or suspected allergy to
propofol or midazolam, suspected pregnancy, gross obesity,
hyperlipemia, moribund state, history of alcoholism orintake of anti-anxiety drugs or hypnotics, chronic renal
failure, coma by cranial trauma or neurosurgery or un-
known etiology or status epilepticus, and unwillingness to
provide informed consent by patients or their authorized
surrogates following ICU admission.
Study procedures
Randomization
The eligible patients were randomly assigned in a 1:1:1
manner to receive midazolam, propofol, or sequential use
of midazolam and propofol. Each assignment was con-
cealed by random selection of opaque, sealed envelopes
for consecutive patients from a box of 135 envelopes.
Every envelope contained a number by a random allocation
process using a computer-generated random block design.
Treatment interventions
All patients received continuous intravenous fentanyl
for analgesia with a bolus dosage of 1 to 2 μg/kg and a
maintenance dosage of 1 to 2 μg/kg/hour. Patients allocated
to the midazolam group (group M) were treated with an
infusion bolus of 0.03 to 0.30 mg/kg and continuous infu-
sion of 0.04 to 0.20 mg/kg/hour, with the dosage adjusted
to achieve the desired level of sedation. Patients allocated
to the propofol group (group P) received an infusion bolus
of 0.50 to 3.00 mg/kg and continuous infusion of 0.50 to
3.00 mg/kg/hour, with the dosage adjusted to achieve the
desired level of sedation. Patients allocated to the sequential
use of midazolam and propofol group (group M-P) first
received midazolam by the same method as group M.
When patients met the sequential criteria, midazolam
was switched to propofol, which was administered at
the maintenance dosage of 0.50 to 3.00 mg/kg/hour.
Patients passed the spontaneous breathing trial (SBT)
safety screen when they showed adequate oxygenation
(oxygen partial pressure ≥60 mmHg, fraction of inspired
oxygen ≤50%, and positive end-expiratory pressure ≤10
cmH2O), hemodynamic stability with no evidence of myo-
cardial ischemia and hypotension, and no significant use
of vasopressors (dopamine or dobutamine ≤5 μg/kg/mi-
nute or norepinephrine ≤2 μg/minute) [17].
The Riker sedation–agitation scale (SAS) [18,19] was
used to assess the sedation quality in each group. According
to our local sedation procedure, the nurses continuously
monitored the sedation depth and adjusted the dosages of
sedative and analgesic drugs to maintain the sedation target
level to 3 or 4 points of degree on the SAS scale. SAS
scores were recorded every 4 hours (or more frequently
when indicated) by the nursing staff to ensure correct titra-
tion of the sedative infusion.
Sedation quality was calculated as follows:
Sedation satisfaction degree ¼ times that SAS score in the
target level range=total evaluation times 100%:
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were assessed every morning by the physicians with a
daily interruption of the continuous sedation safety screen
[17] when there were no contraindications, including
severe hypoxemia, myocardial ischemia, hypertensive
crisis, status asthmaticus, sustained agitation with the
increased use of sedation drugs, and treatment with
neuromuscular blockers. Subsequently, the sedative and
analgesic infusion was interrupted until the patients
were awake, determined based on the following three
simple tasks: opening their eyes, squeezing the hand
and moving fingers, and expressing discomfort. When
patients developed sustained agitation, marked dyspnea,
pulse oxymetry <88% for ≥5 minutes or arrhythmias,
sedatives were restarted at one-half of the previous dose
and then titrated to achieve the target sedation level.
The patients were reassessed the following morning.
Weaning and extubation
Starting the next day after enrolment, the respiratory
therapists managed patients with the SBT safety screen
every morning. Patients in each group who passed the
SBT safety screen underwent a 30-minute SBT with a
pressure support ventilation of 8 cmH2O, positive end-
expiratory pressure of 5 cmH2O, and fraction of inspired
oxygen of 40% [20]. Patients failed the SBT trial if their
respiratory rate was >35 breaths/minute or <8 breaths/
minute; they showed hypoxemia (oxygen saturation <90%),
abrupt changes in mental status, hemodynamic instability
with heart rate and blood pressure changing more than
20% from the previous level, or acute cardiac arrhythmia,
tachycardia (>140 beats/minute), or bradycardia (<60 beats/
minute); they showed marked dyspnoea; or they showed
use of accessory muscles or abdominal paradox. The venti-
lation support level was immediately restored for the
patients who failed the SBT. Patients were reassessed
the following morning. Patients passed the SBT if they
did not exhibit any failure signs. When the SBT was
successful, physicians and respiratory therapists decided
to extubate the patients, including timing the discharge
of the patients from the ICU.
Outcome measurements
The primary outcome measures included the recovery
and extubation time, which were defined as the time
from the cessation of sedation until awakening and extu-
bation, respectively. The data were also collected for the
duration of sedation, duration of mechanical ventilation,
length of stay in ICU and hospital, ICU mortality and
hospital mortality, occurrence of hypotension (decrease
in systolic blood pressure >20%) during the sedation
period, presence or absence of agitation during the 4 hours
after stopping sedation, serum triglyceride concentrations
at admission and the stopping of sedation, and theincidence of acute kidney injury according to Acute Kid-
ney Injury Network criteria during the study period [21].
The secondary endpoints were calculation of the cost
of sedation, the primary monetary pharmaceutical costs
of sedation and total ICU costs (including ICU therapy
and sedation). After patients were transferred out of
the ICU, their recollection to mechanical ventilation-
related events (rolling over, suction, and endotracheal
tube stimulation and pain) were recorded using a ques-
tionnaire. The patients responded from the following
options: unbearable memory, bearable memory, and no
memory.Statistical analysis
Statistical power was estimated using reduction in recovery
time as the primary outcome. The mean (±standard devi-
ation) recovery time for midazolam was 54.7 ± 12.3 hours
in the long-term sedation group (that is, >7 days) according
to Carrasco and colleagues [7]. A sample size of 105 (35
patients in each group) was thus considered adequate to
detect a 15% relative reduction in recovery time for propo-
fol or the sequential use of midazolam and propofol with
90% power and a two-sided significance level of 0.05. As
some patients were severely ill or expected to abandon the
treatment, 135 patients were enrolled for the study in
order to manage the drop-outs.
Values of normal and non-normal distributions were
expressed by mean ± standard deviation and median,
respectively. The differences in normally distributed data
of the three groups were compared with one-way analysis
of variance. The data between any of the two groups were
analyzed with Student–Newman–Keuls methods of analysis
of variance. P < 0.05 was considered statistically significant.
Non-normally distributed parameters were compared with
Kruskal–Wallis analysis of variance, and in the presence of
significant difference in the three groups (P < 0.05) the data
between any of the two groups were analyzed with Mann–
Whitney analysis of variance with the value of α adjusted
to 0.017. Nominal data were analyzed by either the
chi-squared test or Fisher's exact test. Statistically signifi-
cant differences between any two groups were further
compared with the value of α adjusted to 0.017.Results
A total of 135 patients were enrolled in the study. We
excluded 11 patients because their condition deteriorated
rapidly and they died in the 48 hours after admission. A
total of 104 patients completed the study protocol, 11 pa-
tients withdrew (including three patients who were trans-
ferred to the Tibet Chengban branch of our hospital, and
eight patients who were transferred to their local hospitals
and two of these patients who died), seven patients had
tracheotomy, and two patients showed therapeutic failure
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included in the intention-to-treat analysis: 43 patients
were sedated with midazolam (group M), 42 patients se-
dated with propofol (group P), and 39 patients were
treated with midazolam and propofol sequentially (group
M-P). No differences were observed among the groups
with respect to demographics (age, sex and weight) or
baseline parameters of SAS score, Sequential Organ Fail-
ure Assessment score [22], and diagnosis for admission to
the ICU (shown in Table 1).
Quality of sedation
The mean percentages for total times of adequate sedation
in group M, group P and group M-P were 78%, 84% and
86%, respectively (P > 0.05). The percentage of agitated
patients (13 patients were missing assessments) in group
M (48.7%, 19/39) was higher than in group P (22.2%, 8/36;
P = 0.03) and group M-P (19.4%, 7/36; P = 0.01). The per-
centage of total evaluation times of sedation reached for
each degree of SAS scores with propofol, midazolam, and
sequential use of midazolam and propofol are shown in
Figure 1.
Study outcomes
Data for the outcome variables determined using an
intention-to-treat analysis are presented in Table 2. No
difference was detected in the median doses of fentanyl
among groups (P = 0.26): group M, 0.86 (interquartile
range (IQR), 0.66) μg/kg/hour; group P, 0.92 (IQR, 0.13)Table 1 Baseline demographic data
Variable Group M (n = 43) G
Age (years) 54.8 ± 13.6 55
Weight (kg) 60.1 ± 10.2 58
Gender (male/female) 26/17 24
SOFA score at enrollment 7.9 ± 2.5 8.
SAS score at enrollment 5.6 ± 0.9 5.







Vascular surgery 1 2
Liver transplant 1 1
Abdominal surgery 4 5
Values are expressed as mean ± standard deviation. CHF, congestive heart failure; COP
midazolam and propofol group; group P, propofol group; SAS, Riker sedation–agitation
admission. Normally distributed data were compared using one-way analysis of v
comparisons. Nominal data comparisons were based on either the chi-square tesμg/kg/hour; group M-P, 0.78 (IQR, 1.03) μg/kg/hour. No
significant differences were observed in the duration of
sedation and the length of stay in ICU and hospital
among groups (P > 0.05); however, the midazolam sedation
time in group M-P was shorter than in group M (P = 0.01).
The recovery times in group M, group P and group M-P
were 58.0 (IQR, 39.0) hours, 1.5 (IQR, 1.0) hours, and 1.0
(IQR, 1.0) hours, respectively. The extubation times were
45.0 (IQR, 24.5) hours, 3.0 (IQR, 1.0) hours, and 2.0 (IQR,
1.5) hours, respectively. The mechanical ventilation times
were 192.0 (IQR,124.0) hours, 126.0 (IQR, 71.7) hours, and
114.8 (IQR, 95.5) hours, respectively, for the three groups.
These values in group M were significantly longer than
in the other two groups (P < 0.05), but no significant
differences were seen between group P and group M-P
(P > 0.05). No differences in ICU mortality, hospital mor-
tality, incidence of acute kidney injury, or numbers of
patients received continuous renal replacement therapy
were detected among groups (P > 0.05).
Data for the study outcomes of the 104 patients com-
pleting this study protocol using treatment-received ana-
lysis are presented in Table 3. Patients of group P and
group M-P were both associated with earlier extubation,
faster recovery and shorter mechanical ventilation than
those in group M (P < 0.05). The ICU duration in group
M-P was shorter than in group M (P = 0.016). There
were no differences in the duration of sedation, hospital
length of stay, ICU mortality, or hospital mortality among
groups (P > 0.05).roup P (n = 42) Group M-P (n = 39) P value
.9 ± 18.0 53.2 ± 16.8 0.75
.4 ± 9.8 59.6 ± 9.2 0.71
/18 24/15 0.91
3 ± 2.0 9.0 ± 2.0 0.10









D, chronic obstructive pulmonary disease; group M, midazolam group; group M-P,
scale at ICU admission; SOFA, Sequential Organ Failure Assessment at ICU
ariance. The Student–Newman–Keuls test was used for post hoc multiple
t or Fisher's exact test.
Figure 1 Percentage of total evaluation times of sedation reached for each degree of Riker sedation–agitation scale score with propofol,
midazolam, and sequential use of midazolam and propofol.
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in the ICU
Non-normally distributed data pertaining to the pharma-
ceutical sedation costs and the total cost of ICU treatment
are presented in Table 4. The median pharmaceutical
costs of sedation in group M, group P, and group M-P
were 1,982 (IQR, 2,348) yuan, 3,744 (IQR, 4,296) yuan,
and 1,969 (IQR, 1,590) yuan, respectively. The cost of
group P was significantly higher than for group M and
group M-P (P < 0.01), while no differences were observed
between group M and group M-P. The total costs of ICU
treatment were 81,123 (IQR, 41,311) yuan, 66,941 (IQR,
55,123) yuan, and 57,634 (IQR, 55,474) yuan in the three
groups, respectively. The cost of group M-P was distinctly
lower than for group M and group P, but the significantTable 2 Study outcomes using intention-to-treat analysis




Sedation time (hours) 142.0 (94.5) 120.0 (
Midazolam sedation time (hours)a 142.0 (94.5) –
Mechanical ventilation time (hours) 192.0 (124.0) 126.0 (
Recovery timeb (hours) 58.0 (39.0) 1.5 (1.0
Extubation timec (hours) 45.0 (24.5) 3.0 (1.0
ICU duration (days) 17.0 (7.5) 10.0 (1
Length of stay in hospital (days) 23.0 (26.5) 17.0 (4
Incidence of AKI 9 (20.9%) 8 (19.0
Numbers of patients receiving CRRT 4 (9.3%) 3 (7.1%
ICU mortality 7 (16.3%) 6 (14.3
Hospitalization mortality 10 (23.3%) 7 (16.7
Data are expressed as median (interquartile range) for non-normally distributed dat
for non-normally distributed data comparisons, and the nominal data comparisons
of a significant difference in the three groups (P < 0.05), the parameters between any t
acute kidney injury; CRRT, continuous renal replacement therapy. aMedazolam sedatio
t test. bTime from the stopping of sedation until awake: missing assessments for the p
patients in group M, six patients in group P, and three patients in group M-P). cTime fr
patients completing treatment (including 37 patients in group M, 35 patients in group
therapeutic failure, and those who underwent tracheostomy without determining thedifference was detected only between group M and group
M-P (P < 0.01).
Data pertaining to the pharmaceutical sedation costs and
total ICU cost analysis by treatment received are presented
in Table 5. The pharmacy cost of group M-P was signifi-
cantly lower than for group P (P < 0.01) and its total ICU
cost was significantly lower than for group M (P = 0.015).
Memories about discomfort to mechanical
ventilation-related events
A total of 135 patients were enrolled in the study, 28 pa-
tients were lost to follow-up, and 104 patients completed
the questionnaire on their recollection of mechanical
ventilation-related events. Their combined responses to




P value Post hoc test
(P < 0.017)
70.0) 112.5 (101.0) 0.47
77.0 (82.0) <0.01
71.7) 114.8 (95.5) 0.01 1 vs. 2; 1 vs. 3
) 1.0 (1.0) <0.01 1 vs. 2; 1 vs. 3
) 2.0 (1.5) <0.01 1 vs. 2; 1 vs. 3
6.0) 12.5 (8.0) 0.04
0.0) 28.5 (31.5) 0.24
%) 11 (28.2%) 0.59
) 5 (12.8%) 0.70
%) 4 (10.3%) 0.76
%) 6 (15.4%) 0.68
a or number (%) for nominal data. Kruskal–Wallis analysis of variance was used
were based on either the chi-squared test or Fisher's exact test. In the presence
wo groups were further compared with the value of α adjusted to 0.017. AKI,
n times of group M and group M-P were analyzed by independent two-sample
atients withdrawing from treatment or suffering from therapeutic failure (four
om the stopping of sedation until extubation: exposure calculation was based on
P, and 32 patients in group M-P), patients withdrawing treatment and suffering
extubation.
Table 3 Analysis of treatment outcomesa






P value Post hoc test
(P < 0.017)
Sedation time (hours) 142.0 (94.5) 120.0 (70.0) 112.5 (101.0) 0.73
Mechanical ventilation time (hours) 192.0 (124.0) 126.0 (71.7) 114.8 (95.5) 0.02 1 vs. 2; 1 vs. 3
Recovery timeb (hours) 45.0 (26.0) 1.5 (1.0) 1.0 (1.0) <0.01 1 vs. 2; 1 vs. 3
Extubation timec (hours) 45.0 (24.5) 3.0 (1.0) 2.0 (1.5) <0.01 1 vs. 2; 1 vs. 3
Length of stay in hospital (days) 23.0 (26.5) 17.0 (40.0) 28.5 (31.5) 0.24
ICU duration (days) 17.0 (7.5) 10.0 (16.0) 12.5 (8.0) 0.04 1 vs. 3
ICU mortality 5 (13.5%) 6 (17.1%) 4 (12.5%) 0.85
Hospitalization mortality 7 (18.9%) 7 (20.0%) 4 (12.5%) 0.68
Data expressed as median (interquartile range) for non-normally distributed data or number (%) for nominal data. Kruskal–Wallis analysis of variance was used
for non-normally distributed data comparisons, and the nominal data comparisons were based on either the chi-squared test or Fisher's exact test. In the presence of a
significant difference in the three groups (P < 0.05), the parameters between any two groups were further compared with the value of α adjusted to 0.017. aCalculation
of 104 patients in the per-treatment-received analysis. bTime from the stopping of sedation until awake. cTime from the stopping of sedation until extubation.
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able memories involving these events of discomfort in
group M-P was lower than the other two groups. Statis-
tically significant difference was only detected between
group M and group M-P (P < 0.01). The proportion of
bearable memories in group M was lower than in the
other two groups (P < 0.01). The proportion with no
memory in group M and group M-P was similar, and
higher than in group P. The only significant difference
was detected between group M and group P (P < 0.01).
Adverse effects
Hypotension occurred in 22 patients (52.4%) of group
P, 10 patients (23.3%) of group M and eight patients
(20.5%) of group M-P during the sedation period, includ-
ing 10 episodes of unacceptable hypotension (decrease
in systolic blood pressure >40 mmHg or systolic blood
pressure <80 mmHg: three episodes in group M, five
episodes in group P, and two episodes in group M-P).
The incidence of hypotension in group P was significantly
higher than in the other two groups (P = 0.01). No patients
showed hypertriglyceridemia in group P and group M-P.
Fifteen patients died during the ICU stay (nine due to
multiorgan failure, two due to refractory hemorrhage after
operation, and four due to severe acute respiratory distress
syndrome).
Discussion
Our study showed that the sequential use of midazolam
and propofol for long-term sedation was an effective andTable 4 Pharmacoeconomics of sedation in the ICU




Pharmaceutical sedation cost (yuan) 1,982 (2,348) 3,744 (
Total cost of treatment in ICU (yuan) 81,123 (41,311) 66,941
Data expressed as median (interquartile range). Kruskal–Wallis analysis of variance w
three groups (P < 0.05), the parameters between any two groups were further compsafe sedation protocol. The study showed a less frequent
incidence of agitation, faster recovery, earlier extubation
and lower total ICU cost, and had a trend to accelerate
ICU discharge compared with midazolam alone. The
protocol was associated with less cost of pharmaceutical
sedation, and less incidence of hypotension compared with
propofol alone. No patients showed hypertriglyceridemia
with propofol used alone or sequentially. The use of pro-
pofol in the long-term sedation was associated with faster
recovery, earlier extubation and shorter mechanical venti-
lation, increased incidence of hypotension and higher
pharmaceutical sedation costs than midazolam.
In the present study, no differences were seen in terms
of adequate levels of sedation among the three groups.
This finding was consistent with the previous published
results [23]. The quality of sedation of midazolam and pro-
pofol (used alone or sequentially) was similar. Withdrawal
symptoms may occur in ICU patients with long-term
exposure to benzodiazepine sedatives [24]. Midazolam
is a water-soluble benzodiazepine with a rapid onset
and a short duration of action, withdrawal syndrome
(including agitation) immediately following cessation.
The rate of agitation after interruption of sedation in
group M-P was significantly lower than group M, similar
to the results of Saito and colleagues who found that the
rate of agitation evaluated after extubation in group M-P
(8%) was significantly lower than in group M (54%) [23].
Although withdrawal syndrome in critically ill patients
may be attributed to other causes, such as alcohol or




P value Post hoc test
(P < 0.017)
4,296) 1,969 (1,590) <0.01 1 vs. 2; 2 vs. 3
(55,123) 57,634 (55,474) 0.04 1 vs. 3
as used for data comparison. In the presence of significant difference in the
ared with the value of α adjusted to 0.017.
Table 5 Pharmacoeconomics of sedation in the ICUa using treatment analysis






P value Post hoc test
(P < 0.017)
Pharmaceutical sedation cost (yuan) 1,981 (2,536) 3,538 (4,075) 2,143 (2,032) < 0.01 1 vs. 2; 2 vs. 3
Total cost of treatment in ICU (yuan) 86,117 (45,269) 6,748 (44,715) 59,756 (49,383) 0.04 1 vs. 3
Data expressed as median (interquartile range). Kruskal–Wallis analysis of variance was used for data comparison. In the presence of significant difference in the
three groups (P < 0.05), the parameters between any two groups were further compared with the value of α adjusted to 0.017. aCalculation of 104 patients in the
per-treatment-received analysis.
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with addiction. The decreased incidence of agitation in
group M-P may be attributed to a period of propofol infu-
sion before stopping sedation, masking withdrawal symp-
toms associated with discontinuation of midazolam.
Many studies demonstrated that the use of propofol
for long-term sedation in the ICU significantly shortened
the extubation and recovery times, in comparison with
midazolam [6-8,12,13]. In the present study, the average
recovery and extubation times and the mechanical venti-
lation time in group P and group M-P were significantly
shorter than in group M (P < 0.05). The differences in
recovery and extubation times between group P and
group M were in accordance with the findings of Hall
and colleagues, showing that the extubation time in
long-term sedation (more than 3 days) was 46.8 hours in
patients sedated with midazolam and 8.4 hours in patients
sedated with propofol [6]. The recovery time was 54.7 and
1.8 hours, respectively, for both the groups. While Saito
and colleagues reported that the recovery time in group
M-P was only 3 hours shorter (average) than group M,
the sequential use of midazolam and propofol was not
associated with significant advantage [23]. In the study
conducted by Saito and colleagues, 13 patients with
midazolam were switched to propofol approximately
24 hours before the expected cessation of sedation [23].
When patients were sedated with midazolam for a longer
time, extubation delays of up to 49 hours or even longer
were reported [13,25]. After interruption of midazolam
infusion, the recovery time and extubation time exhibited
individual differences [2,6]. The recovery time was longer
under signs of extreme agitation, with the larger dosage
and more frequent administration of the sedative. There-
fore, based on the need for tracheal intubation, respira-
tory support could probably be synchronized with theTable 6 Recall of actual mechanical ventilation-related events
Data 1 Group M 2 Group P
Number of total events (cases) 148 (37) 140 (35)
Unbearable memories 37 (25.0%) 26 (18.6%)
Bearable memories 65 (43.9%) 89 (63.6%)
No memory 46 (31.1%) 25 (17.9%)
Data expressed as number (percentage). Data comparisons were based on the chi-s
(P < 0.05), the parameters between any two groups were further compared with therequirement for sedation. The switching from midazo-
lam to propofol was based on the weaning process after
the patients passed the SBT safety screen. Midazolam
was switched to propofol as early as possible in an ef-
fort to mask the accumulation of midazolam and also
to relatively shorten the duration of midazolam infu-
sion, and then produce more rapid awakening and earlier
extubation, and to shorten the duration of mechanical
ventilation. Midazolam and fentanyl used in the long
term may result in drug accumulation and delayed drug
effect, especially in patients with chronic renal failure.
No patient with chronic renal failure was present in the
three groups. Also, during the study period, no differences
existed in the incidence of acute kidney injury and the
number of patients receiving continuous renal replace-
ment therapy among the group (P > 0.05).
In this study, the ICU duration in group M-P was
shorter than in group M (P = 0.016) in the per-treatment-
received analysis, and using an intention-to-treat analysis
the sequential use of midazolam and propofol also had
a trend to accelerate ICU discharge compared with
midazolam alone (P = 0.018). Comparing propofol with
midazolam in the long-term sedation, the role of propofol
sedation in accelerating ICU discharge is still controver-
sial. The studies conducted by Carrasco and colleagues
and Barrientos-Vega and colleagues demonstrated that
the use of propofol was associated with earlier ICU
discharge [7,13]. However, Sanchez-Izquierdo-Riera and
colleagues and Hall and colleagues (using post hoc analysis)
found that the length of ICU stay was longer for propofol-
sedated patients than midazolam-sedated patients [6,11].
Problems persisted following discharge of patients after
extubation from the ICU. The patient's disease process still
required further ICU care after extubation. Unfortunately a
shortage of floor beds was also seen.(cases)
3 Group M-P P value Post hoc test
(P < 0.017)
128 (32)
15 (11.7%) 0.02 1 vs. 3
81 (63.3%) <0.01 1 vs. 2; 1 vs. 3
32 (25.0%) 0.03 1 vs. 2
quared test. In the presence of significant difference in the three groups
value of α adjusted to 0.017.
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http://ccforum.com/content/18/3/R122In this study, the pharmaceutical cost of sedation and
the total ICU cost were considered for the cost–benefit
analysis of sedation in the three groups. The pharmaceut-
ical sedation costs in group P were significantly higher
than for group M and group M-P. Additionally, the total
ICU cost in group M was the highest in the three groups,
but the only statistically significant difference was mea-
sured between group M-P and group M. Carrasco and
colleagues and Weinbroum and colleagues found that
the pharmaceutical cost of propofol was higher than
midazolam in the long-term sedation [7,14]. Barrientos-
Vega and colleagues reported for the long-term sedation
that the cost attributed to sedation of midazolam was
significantly lower than for propofol and the cost per
patient in the propofol group (including ICU therapy
and sedation with midazolam) was $1,362 less than in
the midazolam group [13]. Although there are remarkable
differences in the cost of sedation with these two agents,
the economic effect was more favorable for propofol than
for midazolam due to a shorter weaning time associated
with propofol administration. The sequential use of mid-
azolam and propofol produced the greatest cost–benefit
of sedation, compared with propofol, due to the decrease
in the pharmaceutical sedation cost. Compared with mid-
azolam, the sequential use decreased the total ICU cost
through the decrease in the mechanical ventilation time
and length of ICU stay.
Research showed that midazolam produced anterograde
amnesia and the amnesic effect was better than for propo-
fol [14]. In this study, the rates of unbearable memories in
group M-P was apparently lower than in the other two
groups. The proportion with no memory in group M and
group M-P was higher than in group P. These results
showed that amnesia was evident when midazolam and
propofol was sequentially used for sedation in the critically
ill mechanically ventilated patients.
A higher number of therapeutic failures because of
sedative inefficacy was seen in the propofol group com-
pared with the midazolam group [26]. We also found
that two patients had therapeutic failure in group P, due
to inadequate sedation at the highest dosage of sedative.
Cardiovascular depression was one of the adverse effects
with both sedatives. Hypotension was greater with pro-
pofol than midazolam during induction [7,8,11,12,14,27].
In this study, the incidence of hypotension in group M-P
was significantly lower than in group P, as midazolam
was switched to propofol without a loading dose. All of
the events were quickly resolved with vasopressor agents
or plasma volume expansion [28]. The use of propofol
for long-term sedation was associated with hypertriglyc-
eridemia [7,8,11,13]. In the patients sedated with propofol
during the this study period, propofol was considered
part of the nutrition support, and the patients' calorie
intake from propofol infusion was deducted from theirparenteral nutrition or enteral nutrition. Hence, none of
these patients presented with hypertriglyceridemia. Further-
more, no other serious adverse events were observed in
the study.
There are limitations to this study. The study was not
blinded, as the physical appearance of the two sedatives
was obviously different. A possibility of knowledge bias
by the nurses was another limitation. However, almost
200 nurses were randomly involved in the care of all the
patients during the ICU stay in our sedation protocols.
Hence, the likelihood of bias was negligible. Delirium
was not assessed as it was left to the treating physicians.
Conclusion
Compared with midazolam, the sequential use of mid-
azolam and propofol for long-term sedation reduced the
incidence of agitation after the cessation of sedation.
This sequential use was associated with a faster recovery,
earlier extubation, a shorter mechanical ventilation time
and a trend to accelerate ICU discharge as well as
decreased total ICU cost. Other advantages included
less pharmaceutical sedation cost, and lower incidence of
hypotension compared with propofol alone. The sequen-
tial use of midazolam and propofol was therefore a safe
and effective sedation protocol, with higher clinical effect-
iveness and better cost–benefit ratio than midazolam
or propofol alone in the long-term sedation of critically
ill, mechanically ventilated patients. Further research is
recommended to elucidate the clinical application of
this protocol.
Key messages
 The sequential use of midazolam and propofol for
long-term sedation was an effective and safe sedation
protocol.
 Compared with midazolam, the sequential use of
midazolam and propofol reduced the incidence of
agitation after the cessation of sedation, led a faster
recovery, earlier extubation and shorter mechanical
ventilation time, and had a trend to accelerate ICU
discharge and lowered the total ICU cost.
 The sequential use of midazolam and propofol was
associated with less pharmaceutical sedation cost,
and a lower incidence of hypotension compared
with propofol alone.
 The use of propofol in the long-term sedation was
associated with faster recovery, earlier extubation
and shorter mechanical ventilation, increased inci-
dence of hypotension and higher pharmaceutical
sedation cost than midazolam.
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